Key result
This review discusses the findings of the Diuretic Optimization Strategies Evaluation (DOSE) trial regarding loop diuretic dosing and administration in acute decompensated heart failure.
Why the study?
What are the implications of the DOSE trial findings on loop diuretic dosing strategies for acute decompensated heart failure?
What are the implications of the DOSE trial findings on loop diuretic dosing strategies for acute decompensated heart failure?
This review discusses the findings of the DOSE trial and its implications for optimizing loop diuretic dosing in acute decompensated heart failure.
Answers are grounded in this paper and cite their sources.
Refines loop diuretic strategies in acute HF; extends DOSE trial evidence to hospital pharmacy practice.
Acute decompensated heart failure (ADHF) is a major problem among the elderly requiring frequent hospitalizations. Although the vast majority of patients with ADHF require loop diuretic therapy to control symptoms, guidelines for their use have been driven primarily by small nonrandomized trials and observational studies. Ongoing debate has centered on the risks of adverse effects including renal dysfunction and the most appropriate method of administration to minimize these risks. Recently, a large prospective randomized trial, the Diuretic Optimization Strategies Evaluation (DOSE), addressed these issues. This article will review the findings of this trial and the implications for clinical practice.
No takes yet. Share an insight, caveat, or question.
Patricia Howard (2011) conducted a review in Acute decompensated heart failure (ADHF). Loop diuretic therapy was evaluated. This review discusses the findings of the Diuretic Optimization Strategies Evaluation (DOSE) trial regarding loop diuretic dosing and administration in acute decompensated heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: